Peptides for joints and recovery — what research has explored for tendons, ligaments, and cartilage

Musculoskeletal injuries occupy a strange place in medicine. The diagnosis is often clear; the treatment is often less so. Surgery is reserved for ruptures. Anti-inflammatories blunt the acute phase but may impair longer-term tissue remodeling. Platelet-rich plasma injections are widely used and inconsistently effective. The gap between what medicine can diagnose and what it can reliably repair is wide enough that a substantial number of athletes, aging active adults, and post-surgical patients have become interested in peptide research — not because the evidence base is mature, but because the mechanistic logic is compelling and the conventional options have real limitations.

The honest framing upfront: most musculoskeletal peptide research has been conducted in rodent and animal models. Human clinical data in this area is limited, largely observational, and in many cases absent. This is not a reason to dismiss the landscape — animal models of tendon repair, cartilage degradation, and ligament healing are mechanistically informative — but it is context that matters when evaluating claims. What follows is a map of the compounds that appear in clinical and research conversations about musculoskeletal recovery, what mechanisms they target, and where the evidence actually stands.

BPC-157 is the compound that dominates this space. It is a synthetic pentadecapeptide derived from a naturally occurring protein in gastric juice — Body Protection Compound, hence the name — and it has a research history going back to the 1990s, primarily from Croatian laboratories. The mechanism picture is unusually rich for a compound in this category: BPC-157 appears to promote angiogenesis, the formation of new blood vessels, in healing tissue; to accelerate fibroblast migration, which is essential for laying down new connective tissue; to upregulate growth factor receptors including those for VEGF and EGF; and to exhibit anti-inflammatory properties through modulation of prostaglandin and nitric oxide pathways. In animal models, these properties translate to measurably faster healing of tendons, ligaments, muscles, and bone — with studies demonstrating accelerated tendon-to-bone attachment, improved repair of Achilles tendon injuries, and faster recovery from muscle crush injuries. The human evidence is where the picture becomes more complicated. BPC-157 has not completed large-scale controlled human clinical trials for musculoskeletal indications. It is not FDA-approved. The evidence that exists in humans is primarily anecdotal and observational, though the mechanistic plausibility is strong enough that it continues to generate research interest. It is available as a research and compounded peptide.

Thymosin Beta-4, and its shorter fragment TB-500, address a different part of the repair equation. Thymosin Beta-4 is an endogenous peptide involved in cell migration and actin regulation — actin being the protein that gives cells their structural framework and allows them to move. In the context of tissue repair, this matters because healing requires injured cells to be cleared and new cells to migrate into the damaged area, and Thymosin Beta-4 appears to facilitate that process. TB-500 is a synthetic fragment of Thymosin Beta-4 that contains what is understood to be the active sequence for this mechanism. Animal research on TB-500 shows effects on cardiac tissue repair, wound healing, and — relevant here — tendon and muscle recovery. Thymosin Beta-4 also has anti-inflammatory properties and has been studied in contexts of corneal injury and cardiac repair. Neither TB-500 nor full-length Thymosin Beta-4 is FDA-approved for musculoskeletal indications, though Thymosin Beta-4 has been studied in cardiac contexts in human trials. The BPC-157 and TB-500 combination has become the most-discussed musculoskeletal peptide stack in optimization circles, based on the logic that their mechanisms are complementary — BPC-157 driving angiogenesis and fibroblast activity while TB-500 supports cell migration and tissue remodeling. That complementarity is mechanistically plausible; whether the combination produces synergistic effects in humans beyond what either compound achieves alone has not been rigorously studied.

ARA-290 is a compound derived from erythropoietin — specifically engineered to retain the tissue-protective properties of EPO without the hematopoietic (red blood cell stimulating) effects. Its primary research interest has been in neuropathic pain and small fiber neuropathy, where it has shown effects on nerve repair and reduction of neuropathic symptoms in human trials including a randomized controlled study in sarcoidosis patients with small fiber neuropathy. In the musculoskeletal recovery context, ARA-290's relevance comes from its nerve-protective properties — injuries to tendons, ligaments, and joints frequently involve neuropathic components, and restoring normal nerve function and reducing neuropathic pain is part of functional recovery. It also has anti-inflammatory properties through the tissue-protective cytokine receptor pathway. ARA-290 is not FDA-approved; it is a research compound.

Cartalax is a tripeptide bioregulator developed in Russia, part of the peptide bioregulator research program initiated by Vladimir Khavinson and colleagues, with a focus on cartilage-specific effects. The research on cartalax is primarily preclinical and originates from Russian scientific literature, with reported effects on chondrocyte proliferation and cartilage matrix synthesis. For anyone whose joint concern is cartilage degradation specifically — the erosion of the cushioning surface in osteoarthritis, for example — the mechanistic target is relevant. The evidence is very limited by Western clinical trial standards, and cartalax is not FDA-approved.

GHK-Cu is a copper-binding tripeptide that occurs naturally in human plasma and is found in higher concentrations in wound fluid, where it appears to support tissue remodeling and collagen synthesis. Most of the research and application of GHK-Cu is in skin contexts, which will be covered in the skin overview, but it has effects on connective tissue broadly — including upregulation of collagen and glycosaminoglycan synthesis, which are relevant to cartilage and tendon matrix integrity. Its relevance to musculoskeletal recovery is more peripheral than BPC-157 or TB-500, but it appears in this landscape as a systemic tissue-support compound.

The growth hormone axis connects to musculoskeletal recovery through IGF-1 — insulin-like growth factor 1, which mediates many of GH's anabolic effects at the tissue level, including in tendons, ligaments, and cartilage. IGF-1 receptors are present in chondrocytes and tenocytes, and IGF-1 signaling supports matrix synthesis and cell proliferation in these tissues. Sermorelin, ipamorelin, and CJC-1295 — the GHRH analogues and GHRPs that stimulate pituitary GH release — therefore have musculoskeletal relevance through the downstream IGF-1 signal. This is a more diffuse and systemic mechanism than BPC-157's direct tissue effects, but it is relevant in contexts where overall tissue repair capacity may be limited by age-related GH decline. MK-677 works through the same downstream pathway via a different receptor mechanism.

IGF-1 LR3 and mechano growth factor (MGF) are more potent, more direct interventions in the IGF-1 axis that appear in some discussions of musculoskeletal recovery, particularly in performance and muscle injury contexts. MGF is a splice variant of IGF-1 that appears in response to mechanical stress and injury in muscle tissue, where it activates satellite cells that are responsible for muscle repair. PEG-MGF is a pegylated version with a longer half-life. The evidence here is mostly animal research. These compounds carry significantly more safety considerations than peptides like BPC-157 or sermorelin — exogenous IGF-1 pathway agonists with strong anabolic effects carry real theoretical risks including effects on cell proliferation in other tissues, and they warrant a much more cautious assessment.

KPV is a tripeptide derived from alpha-melanocyte-stimulating hormone that has shown anti-inflammatory effects in intestinal tissue research and some broader inflammatory contexts. Its presence in musculoskeletal recovery discussions is primarily as an anti-inflammatory support compound rather than a tissue-repair agent, and the evidence base for this specific application is limited.

What the mechanism diversity across this landscape actually means is that different injury types call for different compound considerations. An acute tendon injury with poor vascularity might benefit most from angiogenic support — which is BPC-157's primary claim. A recovery context involving significant neuropathic pain might make ARA-290 more relevant. An older adult with systemic decline in IGF-1 and general tissue repair capacity might find the most value in restoring GH axis signaling. Cartilage-specific problems exist in a different mechanistic category from muscle belly injuries. This is why the "what peptide do I take for my injury" framing tends to produce less useful answers than a thoughtful clinical assessment of what is actually damaged and what physiological process most needs support.

The most important thing to say honestly about this landscape is that progressive mechanical loading remains the primary driver of tendon and ligament remodeling. Tendons respond to load by reorganizing their collagen structure along lines of stress — this is the mechanism that makes physical therapy for tendinopathy effective, and it cannot be replaced by any compound. Peptides, if they have a role in this context, are being explored as complements to the repair process, not substitutes for it. The evidence from animal models suggests they may accelerate a process that mechanical loading drives; they are not likely to drive that process independently.

Evaluation with a prescribing provider who understands musculoskeletal medicine and the current state of peptide research is the appropriate starting point for anyone seriously considering these compounds. The injury pattern, the tissue involved, the patient's age and baseline health, and the evidence profile of each compound all factor into whether any of this makes clinical sense for a given situation.